By Zheng Qi 2020-05-26

Clear, well-documented evidence of malaria parasites that carry partial resistance to artemisinin has now been officially identified across two major global malaria hotspots: the entire Greater Mekong Subregion (GMS) in Southeast Asia, and multiple countries in sub-Saharan Africa, specifically Eritrea, Rwanda, Uganda, and the United Republic of Tanzania. This geographic spread is not a random, isolated trend; it represents a growing public health alert that has drawn the close attention of malaria control programs, researchers, and policymakers across every continent. For decades, the GMS was the only part of the world where artemisinin partial resistance was systematically tracked, but the recent confirmation of independent cases in Africa has expanded the scope of global concern, as this region bears more than 90% of the world’s total malaria burden, with hundreds of millions of people at risk of infection every single year. Unlike the early, scattered anecdotal reports of delayed parasite clearance that once puzzled clinicians, today’s cases are backed by rigorous clinical data, patient follow-up records, and laboratory testing that leave no doubt about the presence of this reduced parasite sensitivity to artemisinin treatments.

A major turning point in the global fight to track this resistance came in late 2013, when an international team of researchers identified a groundbreaking new molecular marker that transformed how scientists study and monitor this phenomenon. Their work confirmed that specific mutations in the PfKelch13 — often shortened to K13 — propeller domain of the malaria parasite’s genome are directly linked to the delayed parasite clearance seen both in controlled laboratory tests and in real human patients after they receive artemisinin-based treatments. Before this discovery, public health teams could only detect partial resistance by carefully tracking patient recovery rates and counting parasite levels in blood samples day after day, a slow, labor-intensive process that often took months to produce reliable results. The K13 molecular marker changed all that: it allows researchers to test small blood samples collected from patients in remote communities, quickly spot the presence of these resistance-linked mutations, and build far more precise, up-to-date maps that show exactly where artemisinin partial resistance is emerging, spreading, or remaining contained. This tool has become the backbone of modern global malaria surveillance, giving countries the ability to spot warning signs long before treatment failures become widespread.

Further genetic analysis of these K13 mutations has revealed a surprising, critical detail about the history of artemisinin partial resistance in Southeast Asia: it very likely first emerged in the GMS as early as before 2001, years before ACTs were widely rolled out as the standard first-line treatment across the region. This early emergence suggests that the resistance did not simply appear as an immediate, direct response to heavy drug pressure from widespread ACT use, but rather developed slowly through a series of subtle genetic shifts in parasite populations over many years. Even more notably, large-scale molecular surveys have proven that artemisinin partial resistance did not spread across the GMS from a single original source. Instead, it emerged independently, on multiple separate occasions, in several different locations scattered across the subregion — a pattern that highlights just how adaptable the malaria parasite can be, and how easily it can develop reduced drug sensitivity under the right conditions.

In Africa, the situation follows a similar, equally concerning pattern. Confirmed cases of artemisinin partial resistance in Eritrea, Rwanda, Uganda, and the United Republic of Tanzania are not the result of parasites spreading across oceans and borders from Southeast Asia. Genetic sequencing has proven that these resistant parasite strains emerged entirely on their own, through separate, independent evolutionary events on the African continent. Based on the latest available surveillance data and preliminary laboratory findings, public health experts also strongly suspect that artemisinin partial resistance is already present in Ethiopia, Namibia, Sudan, and Zambia, even before full official confirmation has been completed. This independent, repeated emergence of resistance across two continents sends a clear message: the world cannot afford to be complacent, and sustained, coordinated global action is more necessary than ever to protect the life-saving power of artemisinin for future generations.

Edited by: Secretariat of the Asia-Pacific Network for Drug and Diagnostics Innovation
Produced by: Zheng Qi
Reviewed by: Zhang Haobing
Tel: 021-64377008-2510 Fax: 021-54108329
Address: 207 Ruijin 2nd Road, Huangpu District,Shanghai, P.R. China  Postcode: 200025